Daily sedation interruption for critically ill patients does not improve outcomes

For critically ill patients receiving mechanical ventilation, daily sedation interruption did not reduce the duration of mechanical ventilation or appear to offer any benefit to patients, and may have increased both sedation and analgesic use and nurse workload, according to a study appearing in JAMA. The study is being published early online to coincide with its presentation at the European Society of Intensive Care Medicine Annual Congress.

"Critically ill patients wean more quickly from mechanical ventilation, with lower risk of , when clinicians use specific strategies to reduce excessive sedation, according to background information in the article. "Protocolized sedation and daily interruption are 2 strategies to minimize sedation and reduce the duration of mechanical ventilation and (ICU) stay."

Sangeeta Mehta, M.D., of Mount Sinai Hospital and the University of Toronto, and colleagues conducted a study to examine whether mechanically ventilated adults managed with both protocolized sedation and daily sedation interruption would receive less sedation and have a shorter duration of mechanical ventilation than patients managed with protocolized sedation alone. The , which included 430 critically ill, mechanically ventilated adults, was conducted in 16 tertiary care medical and surgical ICUs in Canada and the United States between January 2008 and July 2011. Patients received continuous or benzodiazepine infusions and random allocation to protocolized sedation (n = 209) (control) or to protocolized sedation plus daily sedation interruption (n = 214). Using validated scales, nurses titrated infusions to achieve light sedation. For patients receiving daily interruption, nurses resumed infusions, if indicated, at half of previous doses. Patients were assessed for delirium and for readiness for unassisted breathing.

The median (midpoint) time to successful extubation (removal from ) was 7 days in both groups. The researchers found that there were no significant between-group differences in ICU or hospital lengths of stay, hospital mortality, rates of unintentional device removal, delirium, ICU neuroimaging, tracheostomy, or organ dysfunction. Daily sedation interruption was associated with higher average daily doses of midazolam and fentanyl, and more daily boluses of benzodiazepines and opiates.

Overall, average Sedation-Agitation Scale scores per patient were similar in the 2 groups. However, nurse workload was significantly higher in the interruption group.

"In this multicenter randomized trial, we found that among mechanically ventilated patients receiving continuous sedation, the combined use of protocolized sedation and daily sedative interruption did not improve on the clinical outcomes observed with protocolized sedation alone. Patients in the daily interruption group received more opioids and benzodiazepines, and self-assessed nursing workload was higher for patients in the daily interruption group than the control group; however, these findings are of uncertain clinical importance," the authors write.

More information: doi:10.1001/jama.2012.13872

add to favorites email to friend print save as pdf

Related Stories

Early mobilization of patients in ICU improves outcomes

May 18, 2009

Aside from the obvious and immediate health problems that patients undergoing mechanical ventilation face, those who recover often do so with profound loss of strength and mobility that can impair their daily functioning ...

Physician approaches to palliative sedation

Feb 13, 2012

Physicians take two types of approaches to palliative sedation, either mild sedation or deep sedation from the start, and it is important to understand the reasons behind each approach, states an article in CMAJ (Canadian Medical A ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments